

2024 Special Vaccine Order Form Fax: 705-792-3835 or Email: Vaccineorders@smdhu.org

Date: ___

Facility Contact:	Phone #:		Ext.		Facility	Fax #:
Facility Name:	# of Fridges:	Туре:	🗆 Bar		omestic	Purpose Built
• Place orders by Wednesday 3 pm for pick up the follow	Coolers must be between 2 - 8 °C for vaccine to be released					
• Orders must include the previous 4 week temperature	Vaccine order inquiries ext. 8808					

- REFER to the PUBLICLY FUNDED IMMUNIZATION SCHEDULES FOR ONTARIO (June 2022) for # of eligible doses and intervals \geq between doses (product specific tables noted below).
- REFER to the Guidance for Routine & Catch-Up Immunization Services (Version 5 Jan 2024) for temporary program ≻ extensions for 2024.

Initials (First. Last): ______ DOB (YYYY/MM/DD): _____

Vaccine Name	Product / Description	Dose # in Series Requested	Eligibility Criteria <u>(check all that apply)</u>
Bexsero®	Meningococcal B (4CMenB)	Dose: 1 2 3 4 (See Table 14)	Age 2 months through 17 years*: Image: Functional or anatomic asplenia Image: Complement, properdin, factor D deficiency, or primary antibody deficiency Image: Cochlear implant recipient (pre/post implant) Image: Acquired complement deficiency (e.g., receiving eculizumab) Image: HIV *Temporary extension for individuals born in 2002, 2003, 2004, 2005 and 2006 – remain eligible for missed doses until Dec 31, 2024
Nimenrix® Menactra®	Meningococcal C-ACYW135	Dose: 1 2 3 4 Booster (See Table 15)	Age 9 months through 55 years: Image: Functional or anatomic asplenia Image: Complement, properdin, factor D deficiency or primary antibody deficiency Image: Cochlear implant recipient (pre/post implant) Image: Acquired complement deficiency (e.g., receiving eculizumab) Image: HIV
		Dose: 1 2** **only if born in 1964, 1965, 1966) (See Table 15)	Age ≥ 56 years*: □ Functional or anatomic asplenia □ Complement, properdin, factor D deficiency or primary antibody deficiency □ Cochlear implant recipients (pre/post implant) □ Acquired complement deficiency (e.g., receiving eculizumab) □ HIV *Temporary extension for individuals born in 1964, 1965, 1966, 1967 and 1968 – remain eligible for missed doses until Dec 31, 2024.

Location to be picked up (please check):

Barrie	Collingwood	Cookstown	Midland	VIM Order # (for office use only):
Confidentiality				
The contents of	the document(s) accompany	ving this facsimile transmiss	sion are confidential an	d intended only for use by the individual(s) named above.

The contents of the document(s) accompanying this facsimile transmission are confidential and intended only for use by the individual(s) named above. It may contain information that is privileged, confidential, or otherwise protected from disclosure. <u>Any review, dissemination or use of this transmission</u> or its contents by persons other than the addressee is strictly prohibited.

Vaccine Name	Product / Description	Dose # in Series Requested	Eligibility Criteria <u>(check all that apply)</u>	
Avaxim [®] / Havrix [®] / Vaqta [®] Avaxim [®] Pediatric Havrix [®] Pediatric Vaqta [®] Pediatric	Hepatitis A	Dose: 1 2 (See Table 5)	Age ≥ 1 year: Chronic liver disease (including hepatitis B and C) Persons engaging in intravenous drug use Men who have sex with men	
Recombivax HB® / Engerix-B® Recombivax HB® Pediatric Engerix-B® Pediatric	Hepatitis B	Dose: 1 2 3 4 (See Table 7)	Age ≥ 0 years: □ Infant born to HBV-positive mothers: ○ Premature infant weighing < 2,000 grams at birth (4 doses)	
High Dose (Dialysis) Formulation Recombivax HB®	Hepatitis B	Dose: 1 2 3 (See Table 7)	Age ≥ 20 years: Chronic renal disease or on dialysis Chronic liver disease Individuals awaiting liver transplant HIV	
Gardasil®	HPV-9	Dose: 1 2 3 (Table 10 and Table 11)	Males 9 to 26 years*: Men who have sex with men *Temporary extension for males born in 1993, 1994, 1995, 1996, and 1997 – remain eligible for missed doses until Dec 31, 2024.	

Location to be picked up (please check):

Barrie

Collingwood

Cookstown

Midland

VIM Order # (for office use only):

2024-01-25

Confidentiality Notice:

The contents of the document(s) accompanying this facsimile transmission are confidential and intended only for use by the individual(s) named above. It may contain information that is privileged, confidential, or otherwise protected from disclosure. <u>Any review, dissemination or use of this transmission</u> or its contents by persons other than the addressee is strictly prohibited.